Dong-A ST Dapapro confirmed non-inferiority to Forxiga

Dong-A ST announced the results of a comparative clinical trial of the diabetes treatment Dapapro on 6month 8day. The company said Dapapro had demonstrated non-inferiority to the original product. The announcement specified that an effect similar to Forxiga's had been confirmed. It said details such as the clinical design and number of patients should be checked separately in the company's announcement.

Daewoong announced on the same day that efficacy had been observed for the diabetes treatment Enblow in patients from multiple countries. The company said the drug's efficacy had been confirmed through patient data from several countries. It said specific results and the countries involved could be found in the company's materials. Daewoong also said it would announce subsequent clinical plans and regulatory-related schedules separately.

Lunit announced that it had been invited to the AI ecosystem roundtable hosted by Nvidia. The company said it had sought global cooperation in the medical field at the meeting. Lunit said the specific scope of cooperation and joint development details would be determined through discussions in the future. It said the results of discussions with participating companies could be disclosed later.

Some reports on the same day said that global institutional investors were reducing their exposure to Korean stocks. The reports said that large funds were adjusting their portfolios. Specific fund amounts and target stocks were not disclosed. They said that it would be necessary to check for further announcements from each institution to determine whether there would be a market impact.

All four announcements above were made public on 6 month 8 day. Each company said it would provide more information through detailed materials and additional disclosures. Investors and stakeholders were advised to check each company's disclosure materials directly. These are the key facts made public on 6 month 8 day.